COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,593 Articles (22,905 medRxiv, 8,688 bioRxiv)

Most recent first Previous |  Page 43: Articles 421-430  | Next

Extended poly(A) tails are a shared feature of herpesvirus mRNAs
Fuhrmann, E., Toda, S., Leins, J., Cetraro, P., Deshpande, V., Jacobsen, C., Kropp, K. A., Lamars, M. M., Loliashvili, E., Saleban, M., Verstraten, R., Vogt, C., wongwiwat, W., Ouwendijk, W. J., Viejo-Borbolla, A., White, R. E., Wilson, A. C., Burgess, H. M., Depledge, D. P.
10.64898/2025.12.15.694445 — Posted: 2025-12-16
MPXV Clade IIb virus infection in mice leads to prolonged viral replication, macrophage infiltration, and decreased spermatogenesis in the testes.
Swan, C., Sganzerla Martinez, G., Alfajaro, M. M., Rasmussen, A., Kelvin, D. J., Evans, D., Kindrachuk, J., Noyce, R., Kelvin, A. A.
10.64898/2025.12.16.694558 — Posted: 2025-12-16
Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine
Kurhade, C., Chen, W., Li, W., Tompkins, K. R., Martinez, L. T., Rajput, S., Babiarz, E., Yam, A., Lee, S.-A., Shrivastava, S., O'Leary, S., Saha, S., Yao, H., Hao, L., Coffey, T., Couto, C. I. C., Muik, A., Moreno, R. M., Swanson, W., Daroca, P. M., Sahin, U., Anderson, A. S., Swanson, K. A., Allen, P. S., Modjarrad, K.
10.64898/2025.12.15.694478 — Posted: 2025-12-16
Modeling the Cost-Effectiveness of the COVID-19 mRNA-1273 vaccine in the United States
Fust, K., Beck, E., Kohli, M., Cartier, S., Van de Velde, N., Weinstein, M., Joshi, K.
10.64898/2025.12.12.25342164 — Posted: 2025-12-15
Incorporating Genomic Sequences into Stochastic Transmission Modeling to Improve the Analysis of SARS-CoV-2 Transmission Dynamics
Longini, I., Gui, T.
10.64898/2025.12.11.25342070 — Posted: 2025-12-15
Thymidine Phosphorylase Drives SARS-CoV-2 Spike Protein-Induced Lung Tumorigenesis
Wallace, C., Gileles-Hillel, A., Cox, A., Gozal, D., Li, W., Yue, H.
10.64898/2025.12.14.694192 — Posted: 2025-12-15
Development of a Bacterial Colorimetric Reporter System for Functional Screening of SARS-Cov-2 Main Protease Inhibitors Using Plant Preparations (juices): A Proof-of-Concept Study
Issa, S. S., Zelinsky, A., Fayoud, H., Zhidkin, R., Matveeva, T. V.
10.64898/2025.12.12.694002 — Posted: 2025-12-15
Structural Dynamics and Allosteric Communication of a SARS-Like Bat Coronavirus Spike Glycoprotein
Balogun, T., Kearns, F., Calvo-Tusell, C., Tse, A. L., Acreman, C. M., Casalino, L., Lasso, G., Miller, E. H., Chandran, K., McLellan, J. S., Amaro, R. E.
10.64898/2025.12.12.693972 — Posted: 2025-12-15
SARS-CoV-2 Intra-host Variation Shows Evidence of Transmission and Convergent Evolution in a University Surveillance Cohort
Cavalli, L., Taylor, B. P., Schaeffer, B., Turcinovic, J., Connor, J. H., Hanage, W. P.
10.64898/2025.12.12.694004 — Posted: 2025-12-15
Long-term N-Acetylcysteine Treatment Accelerates Improvement in Patient-Reported Outcomes for COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Li, L., zhao, h., Ye, L., He, H., Chai, C., Tong, Y., Zhang, Y.
10.64898/2025.12.10.25342003 — Posted: 2025-12-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).